| abstract |
Biglycan variants and related therapeutic agents and methods of use are provided. The present disclosure provides biglycan-related therapeutic polypeptides that contain substitutions at two serine residues so as not to contain any glycosaminoglycan side chains. Diseases or conditions associated with abnormal levels or activity of biglycan; disorders associated with unstable cytoplasmic membranes, eg, due to unstable dystrophin binding protein complex (DAPC); abnormal MuSK activation or acetylcholine Further provided are methods for treating disorders associated with abnormal synapses or neuromuscular junctions, including disorders caused by receptor (AChR) assembly. Examples of diseases include muscular dystrophy such as Duchenne muscular dystrophy, Becker muscular dystrophy, neuromuscular disorders and neurological disorders. [Selection] Figure 3 |